Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations

被引:16
|
作者
Li, Ning [1 ,2 ]
Yao, Qiu-Mei [1 ,2 ]
Gale, Robert Peter [3 ]
Li, Jin-Lan [1 ,2 ]
Li, Ling-Di [1 ,2 ]
Zhao, Xiao-Su [1 ,2 ]
Jiang, Hao [1 ,2 ]
Jiang, Qian [1 ,2 ]
Jiang, Bin [1 ,2 ]
Shi, Hong-Xia [1 ,2 ]
Chen, Shan-Shan [1 ,2 ]
Liu, Kai-Yan [1 ,2 ]
Huang, Xiao-Jun [1 ,2 ]
Ruan, Guo-Rui [1 ,2 ]
机构
[1] Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
[2] Inst Hematol, Beijing 100044, Peoples R China
[3] Univ London Imperial Coll Sci Technol & Med, Haematol Res Ctr, Dept Med, Div Expt Med, London W12 0HS, England
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
Calreticulin; Mutation; Myeloproliferative neoplasm; Allele burden; JAK2 V617F MUTATION; MYELOPROLIFERATIVE NEOPLASMS; POLYCYTHEMIA-VERA; W515L/K MUTATIONS; JAK2V617F; CALRETICULIN; DISORDERS; FEATURES; SUBTYPES;
D O I
10.1016/j.leukres.2015.02.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CALR mutations are detected in about 50% of persons of predominately European descent with essential thrombocythemia (ET) or primary myelofibrosis (PMF) with wild-type alleles of JAK2 and MPL. We studied 1088 Chinese with diverse myeloproliferative neoplasms including ET (N= 234) and PMF (N=50) without JAK2(V617F) or MPL exon 10 mutations. CALR mutation was detected in 53% (95% CI, 46-60%) of subjects with ET and 56% (95% CI, 41-70%) of subjects with PMF. 152 CALR mutations were identified clustering into 15 types including deletions (N= 8), insertions (N=3) and complex indels (N=4). We also identified 9 new mutations. Mean (+/- SD) mutant allele burden was 31 +/- 12% (range, 0.5-69%). Persons with PMF had higher CALR mutant allele burdens than those with ET (38 +/- 8% vs. 29 +/- 12%; P < 0.001). Amongst persons with CALR mutations, those with PMF had different clinical features from those with ET. These data may be useful for diagnosing ET and PMF in Chinese who are about 40% of all persons with ET and PMF and for monitoring therapy-response. They also highlight similarities and differences in CALR mutations between Chinese and persons of predominately European descent with these diseases. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:510 / 514
页数:5
相关论文
共 50 条
  • [31] JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
    Carobbio, Alessandra
    Finazzi, Guido
    Antonioli, Elisabetta
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Dellacasa, Chiara M.
    Salmoiraghi, Silvia
    Delaini, Federica
    Rambaldi, Alessandro
    Barbui, Tiziano
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (09) : 1016 - 1021
  • [32] The phenotype of JAK2V617F mutant patients with essential thrombocythemia is not related to the burden of mutant allele
    Antonioli, E.
    Guglielmelli, P.
    Poli, G.
    Longo, G.
    Ponziani, V.
    Pancrazzi, A.
    Bosi, A.
    Vannucchi, A. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 335 - 335
  • [33] Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis
    Reis Monte-Mor, Barbara da Costa
    Zalcberg, Ilana
    Correia, Willian Dias
    Coelho, Ana Caroline
    Ayres-Silva, Jackline de Paula
    Solza, Cristiana
    Daumas, Adelmo Henrique
    Bonamino, Martin Hernan
    de Souza Santos, Fabio Pires
    Datoguia, Tarcila Santos
    Pereira, Welbert de Oliveira
    Garcia Lisboa, Bianca Cristina
    Hamerschlak, Nelson
    Campregher, Paulo Vidal
    Ramos, Clarisa Fernandes
    Machado-Neto, Joao Agostinho
    Barbosa Pagnano, Katia Borgia
    Traina, Fabiola
    BLOOD CELLS MOLECULES AND DISEASES, 2016, 60 : 74 - 77
  • [34] Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients
    Koren-Michowitz, Maya
    Hauschner, Hagit
    Shuly, Yulia
    Nagar, Meital
    Ribakovsky, Elena
    Misgav, Mudi
    Gutwein, Odit
    Seligsohn, Uri
    Rosenberg, Nurit
    Nagler, Arnon
    BLOOD, 2014, 124 (21)
  • [35] Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis
    徐泽锋
    ChinaMedicalAbstracts(InternalMedicine), 2016, 33 (03) : 178 - 178
  • [36] Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms
    Lilleskare, Susanne
    Vorland, Marta
    Vo, Anh Khoi
    Aarsand, Aasne K.
    Reikvam, Hakon
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (01): : 3 - 7
  • [37] Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
    Yonal, Ipek
    Daglar-Aday, Aynur
    Akadam-Teker, Basak
    Yilmaz, Ceylan
    Nalcaci, Meliha
    Yavuz, Akif Selim
    Sargin, Fatma Deniz
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 94 - 101
  • [38] Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis
    Zamora, Lurdes
    Xicoy, Blanca
    Cabezon, Marta
    Fernandez, Cristalina
    Marce, Silvia
    Velez, Patricia
    Xandri, Marisol
    Gallardo, David
    Milla, Fuensanta
    Feliu, Evarist
    Boque, Concepcion
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2973 - 2974
  • [39] JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens
    Mansier, Olivier
    Migeon, Marina
    Etienne, Gabriel
    Bidet, Audrey
    Lippert, Eric
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1949 - 1951
  • [40] Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
    Ozdemir, Zehra Narli
    Ipek, Yildiz
    Patir, Puesem
    Ermis, Goezde
    Ciftciler, Rafiye
    Ozmen, Deniz
    Baysal, Mehmet
    Gursoy, Vildan
    Yildizhan, Esra
    Guven, Serkan
    Ercan, Tarik
    Elibol, Tayfun
    Mersin, Sinan
    Genc, Eylem
    Davulcu, Eren Arslan
    Karakus, Volkan
    Erkut, Nergiz
    Gunes, Guersel
    Kucukkaya, Reyhan Diz
    Eskazan, Ahmet Emre
    TURKISH JOURNAL OF HEMATOLOGY, 2024, 41 (01) : 26 - 36